araag2/HINT huggingface dataset:
Clinical trial NCT01075763 (phase 2, status: completed)
Conditions: alzheimer's disease
ICD codes: G30.8, G30.9, G30.0, G30.1
Drugs: interferon beta-1a, placebo
SMILES: [Na+].[Cl-], CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Subjects aged between 50 and 75 years

          -  Subjects diagnosed with AD, according to the Diagnostic and Statistical Manual of
             Mental Disorders, 4th edition (DSM-IV)

          -  Subjects with MMSE score of 20 to 26 (inclusive)

          -  Subjects supervised by a caregiver

          -  Subjects who have been given informed written consent and approval of the Local
             Ethical Committee

        Exclusion Criteria:

          -  Subjects with constant use in the 3 months prior study enrolment of other drugs that
             can modify the course of the disease (e.g. statins, nonsteroidal anti-inflammatory
             drugs [NSAIDs] and steroids) or symptomatic cognitive treatments (e.g. cholinesterase
             inhibitors)

          -  Subjects with modified Hachinski Ischemic Score ≥ 4

          -  Subjects who are unable to undergo neuropsychological evaluation (including
             analphabetism)

          -  Subjects with significant liver (aspartate aminotransferase, alanine aminotransferase
             , alkaline phosphatase > 2.0 times the upper limit of normal [ULN] of the local
             laboratory, or total bilirubin > 1.5 times the ULN of the local laboratory), thyroid
             (according to clinical judgment) or hematological dysfunctions (e.g. leucocytes ≤ 2.0
             * 109/Liter [L]; platelets ≤ 100 * 109/L; hemoglobin ≤ 12 gram/deciliter [g/dL] for
             women and ≤ 13 g/dL for men, serum albumin ≤ 3 g/dL)

          -  Subjects with history (past or recurrent) of depression unresponsive to medication or
             past medical history of suicidal ideation

          -  Subjects with severe cardiac disease (angina, congestive heart failure class 3-4 New
             York Heart Association [NYHA] Functional Classification , or severe arrhythmia)

          -  Subjects with epilepsy

          -  Subjects with concomitant use of hypnotic, anxiolytic, antidepressant, antipsychotic,
             anticholinergic

          -  Subjects with known allergic reactions against IFNs or other components of the applied
             drug
Clinical trial NCT00361972 (phase 2/phase 3, status: terminated)
Conditions: gastroesophageal reflux, asthma
ICD codes: K21.9, K21.00, K21.01, J45.998, J82.83, J45.909, J45.991, J45.20, J45.30, J45.40
Drugs: lansoprazole, placebo
SMILES: CC1=C(OCC(F)(F)F)C=CN=C1CS(=O)C1=NC2=CC=CC=C2N1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Reason stopped: 
    limited recruitment
  
Eligibility criteria:

        Inclusion Criteria:

          1. chronic cough consistent with bronchoreactivity

          2. Gastroesophageal reflux

        Exclusion Criteria:

          1. Severe asthmatics who have been hospitalized within the last 6 months or who have
             required oral steroid use within the last 4 weeks

          2. Severe coronary artery disease

          3. Cigarette/cigar smoking within the last 6 months

          4. Documented allergies affecting the respiratory system

          5. Subjects with contraindications to pH/impedance probe

               1. Hemophilia

               2. Septal deviation

          6. Subjects with contraindications to bronchoscopy as outlined by the American Thoracic
             Society Guidelines

          7. Anticoagulation

          8. Pregnancy

          9. Incarcerated patients

         10. Current oral steroid use (may suppress levels of inflammation)

         11. Upper respiratory infection within the last 2 weeks

         12. Ongoing acid suppression with a proton pump inhibitor, however, patients may be
             included if they have discontinued their proton pump inhibitor within the last 1 month
             with stable asthma symptoms as defined by stable utilization of inhaled steroids
Clinical trial NCT01193101 (phase 2, status: completed)
Conditions: hypertension
ICD codes: I15.0, I97.3, K76.6, P29.2, G93.2, H40.053, I10
Drugs: lcz696, placebo
SMILES: CCCCC(=O)N(CC1=CC=C(C=C1)C1=CC=CC=C1C1=NNN=N1)[C@@H](C(C)C)C(O)=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          1. Patients must give written informed consent before any assessment is performed.

          2. Patients with mild to moderate essential hypertension, untreated or currently taking
             antihypertensive therapy (mean sitting diastolic blood pressure ≥ 95 mmHg and < 110
             mmHg, and mean sitting systolic blood pressure ≥ 140 mmHg and < 180 mmHg).

          3. Patients must be willing and able to undergo ambulatory blood pressure monitoring for
             a 24-hr period at the beginning and the end of the 8-week treatment.

          4. Patient must be able to communicate and comply with all study requirements and
             demonstrate good medication compliance.

        Exclusion Criteria:

          1. Patients with severe hypertension.

          2. Patients with history of angioedema, drug-related or otherwise

          3. Pregnant or nursing women

          4. Women of child-bearing potential , who do not use adequate birth control methods

          5. History or evidence of a secondary form of hypertension.

          6. History of angina pectoris, myocardial infarction, coronary bypass surgery, ischemic
             heart disease, surgical or percutaneous arterial intervention of any kind, stroke,
             TIA, carotid artery stenosis, aortic aneurysm, or peripheral arterial disease.

          7. Diabetes mellitus.

          8. Previous or current diagnosis of heart failure (NYHA Class II-IV).

          9. Clinically significant valvular heart disease at the time of screening.

        Other protocol-defined inclusion/exclusion criteria may apply
Clinical trial NCT00142480 (phase 2, status: completed)
Conditions: biliary tract cancer, gallbladder adenocarcinoma
ICD codes: C24.9, C24.8, C22.0, C22.1, C4A.9, C7B.1, D09.9, C4A.0, C4A.31
Drugs: capecitabine, oxaliplatin, bevacizumab
SMILES: [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1
Eligibility criteria:

        Inclusion Criteria:

          -  Histologically confirmed locally advanced unresectable biliary tract or gallbladder
             adenocarcinoma

          -  Patients with resected biliary tract or gallbladder adenocarcinoma who have residual
             tumor left will also be eligible.

          -  > 4 weeks since time of major surgery

          -  > 2 weeks since time of minor surgery

          -  > 4 weeks since time of major radiotherapy for other malignancy

          -  > 4 weeks since participation in any investigational drug study

          -  > 1 year since treatment for other carcinomas, except cured non-melanoma skin and
             treated in-situ cervical cancer

          -  18 years of age or older

          -  ECOG performance status of 0-2

          -  Life expectancy > 12 weeks

          -  Absolute neutrophil count (ANC) > 1,500/mm3

          -  Hemoglobin > 9.0 gm/dl

          -  Platelets > 100,000/mm3

          -  SGOT < 5 x upper limits of normal (ULN)

          -  Total bilirubin < 2.5 mg/dl

          -  Creatinine clearance > 50 ml/min

        Exclusion Criteria:

          -  Prior chemotherapy or radiation therapy for biliary tract or gallbladder cancer

          -  Peripheral neuropathy of grade 2 or greater

          -  Unstable angina

          -  Symptomatic congestive heart failure

          -  Myocardial infarction < 12 months prior to registration

          -  New York Heart Association classification III or IV

          -  Active or uncontrolled infection

          -  Known existing uncontrolled coagulopathy

          -  Malabsorption syndrome or lack of integrity of the upper gastrointestinal (GI) tract

          -  Prior unanticipated severe reaction to fluoropyrimidine therapy or known sensitivity
             to 5-fluorouracil, or known dihydropyrimidine dehydrogenase (DPD) deficiency

          -  Known brain metastases or carcinomatous meningitis

          -  Pregnant or lactating women

          -  Serious, non-healing wound, ulcer, or bone fracture

          -  Evidence of bleeding diathesis or coagulopathy
Clinical trial NCT00678210 (phase 2, status: completed)
Conditions: psoriasis
ICD codes: L40.0, L40.4, L40.8, L40.9, L40.1, L40.50
Drugs: cp-690,550, cp-690,550, cp-690,550, placebo
SMILES: [H][C@@]1(C)CCN(C[C@]1([H])N(C)C1=NC=NC2=C1C=CN2)C(=O)CC#N, [H][C@@]1(C)CCN(C[C@]1([H])N(C)C1=NC=NC2=C1C=CN2)C(=O)CC#N, [H][C@@]1(C)CCN(C[C@]1([H])N(C)C1=NC=NC2=C1C=CN2)C(=O)CC#N, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Have been diagnosed with plaque psoriasis for at least 6 months.

          -  Have plaque psoriasis covering at least 15% of their total body.

          -  Be a candidate for phototherapy or systemic treatment of psoriasis (either naïve or
             history of previous treatment).

          -  Be willing and able to comply with scheduled visits, treatment plan and other study
             procedures.

        Exclusion Criteria:

          -  Currently have non-plaque forms of psoriasis or drug-induced psoriasis.

          -  Subject cannot discontinue systemic therapies and/or topical therapies for the
             treatment of psoriasis and cannot discontinue phototherapy.

          -  Subject is participating in another trial using an investigational agent or procedure.

          -  Women who are pregnant or breast-feeding or considering becoming pregnant.
Clinical trial NCT01008852 (phase 2, status: completed)
Conditions: active rheumatoid arthritis
ICD codes: M05.9, M06.08, M06.00, M06.011, M06.012, M06.019, M06.021
Drugs: sbi-087, sbi-087, sbi-087, sbi-087, placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Meets the American College of Rheumatology (ACR) 1987 revised criteria for
             classification of Rheumatoid Arthritis (RA) for at least 6 months prior to screening

          -  Active RA as defined by >= 5 swollen and >= 5 tender joints (28-joint count) and at
             least 1 of the following: C-reactive protein >= 10 mg/L or Erythrocyte Sedimentation
             Rate >= 28 mm/h

          -  Must be seropositive as defined by a documented history of rheumatoid factor (RF) or
             anti-cyclic citrullinated peptide (anti-CCP) positivity

          -  Must be receiving a stable route and dose of methotrexate (up to 25 mg weekly)

        Exclusion Criteria:

          -  Any significant health problem other than rheumatoid arthritis

          -  Any clinically significant laboratory abnormalities

          -  Any prior use of B cell-depleting therapy
Clinical trial NCT00531843 (phase 2/phase 3, status: completed)
Conditions: venous thromboembolism
ICD codes: O88.22, O88.23, O88.211, O88.212, O88.213, O88.219
Drugs: fondaparinux sodium
SMILES: CO[C@H]1O[C@H](COS(O)(=O)=O)[C@@H](O[C@@H]2O[C@H]([C@@H](O[C@H]3O[C@H](COS(O)(=O)=O)[C@@H](O[C@@H]4O[C@@H]([C@@H](O[C@H]5O[C@H](COS(O)(=O)=O)[C@@H](O)[C@H](O)[C@H]5NS(O)(=O)=O)[C@H](O)[C@H]4O)C(O)=O)[C@H](OS(O)(=O)=O)[C@H]3NS(O)(=O)=O)[C@H](O)[C@H]2OS(O)(=O)=O)C(O)=O)[C@H](O)[C@H]1NS(O)(=O)=O
Eligibility criteria:

        Inclusion Criteria:

          -  Patients age ≥ 18 years old admitted to San Francisco General Hospital for injury with
             at least one risk factor for venous thromboembolism (VTE).

        Risk factors are: Age ≥ 40 years, pelvic fracture, lower extremity fracture, spinal cord
        injury, shock or head injury, major operative procedure, mechanical ventilation > 3 days,
        venous injury

        Exclusion Criteria:

          -  prisoners

          -  pregnant patients

          -  patients who are anticipated to have a < 5 day length of stay as determined by the
             admitting trauma surgeon

          -  patients who decline to participate in the study
Clinical trial NCT01519778 (phase 2, status: completed)
Conditions: major cutaneous abscess, cellulitis, erysipelas
ICD codes: L03.213, L03.90, L03.211, L03.221, L03.314, L03.315, L03.316
Drugs: tr701 fa
SMILES: CN1N=NC(=N1)C1=CC=C(C=N1)C1=CC=C(C=C1F)N1C[C@H](COP(O)(O)=O)OC1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Male or female patients ≥ 18 years of age

          -  Suspected or documented gram-positive infection from baseline Gram stain or culture.

          -  Cellulitis/erysipelas or major cutaneous abscesses at Screening

        Exclusion Criteria:

          -  Postsurgical or open wound infections

          -  Severe sepsis or septic shock

          -  Uncomplicated skin and skin structure infections such as furuncles, minor abscesses (<
             75 cm2 or area of suppuration not surrounded by cellulitis/erythema), and impetiginous
             lesions

          -  Infections associated with, or in close proximity to, a prosthetic device

          -  Known bacteremia or osteomyelitis at time of screening
Clinical trial NCT00077428 (phase 2, status: completed)
Conditions: recurrent adenoid cystic carcinoma of the oral cavity, recurrent salivary gland cancer, salivary gland adenoid cystic carcinoma, stage iii adenoid cystic carcinoma of the oral cavity, stage iii salivary gland cancer, stage iv adenoid cystic carcinoma of the oral cavity, stage iv salivary gland cancer
ICD codes: C22.0, C22.1, C4A.9, C7B.1, D09.9, C4A.0, C4A.31, C07, C08.0, C08.1, C73, C75.0, C75.1, C75.3, C22.0, C22.1, C4A.9, C7B.1, D09.9, C4A.0, C4A.31, C08.9, D11.9, D11.7, D37.030, D37.031, D37.032, D37.039, C08.9, D11.9, D11.7, D37.030, D37.031, D37.032, D37.039
Drugs: bortezomib, doxorubicin hydrochloride
SMILES: ClCCN(CCCl)P1(=O)NCCCO1, COC1=CC=CC2=C1C(=O)C1=C(O)C3=C(C[C@](O)(C[C@@H]3O[C@H]3C[C@H](N)[C@H](O)[C@H](C)O3)C(=O)CO)C(O)=C1C2=O
Eligibility criteria:

        Inclusion Criteria:

          -  Histologically confirmed adenoid cystic carcinoma of the head and neck

               -  Locally advanced, recurrent, or metastatic disease that is considered incurable
                  by known therapies

          -  Unidimensionally measurable disease

          -  Must not have stable disease for at least 9 months before study entry

          -  No known brain metastases

          -  Performance status - ECOG 0-2

          -  Absolute neutrophil count at least 1,500/mm^3

          -  Platelet count at least 100,000/mm^3

          -  AST and ALT no greater than 2.5 times upper limit of normal

          -  Bilirubin normal

          -  Creatinine normal

          -  Creatinine clearance at least 60 mL/min

          -  LVEF at least lower limit of normal by MUGA

          -  No history of congestive heart failure

          -  No unstable angina pectoris

          -  No cardiac arrhythmia

          -  Not pregnant or nursing

          -  Negative pregnancy test

          -  Fertile patients must use effective contraception

          -  HIV negative

          -  No active or ongoing infection

          -  No prior allergy to compounds of similar chemical or biological composition to
             bortezomib

          -  No other concurrent uncontrolled illness

          -  No psychiatric illness or social situation that would preclude study compliance

          -  No pre-existing neuropathy > grade 1

          -  No other invasive malignancy within the past 5 years except nonmelanoma skin cancer or
             carcinoma in situ of the cervix

          -  See Chemotherapy

          -  No prior anthracyclines, including any of the following:

               -  Doxorubicin

               -  Epirubicin

               -  Daunorubicin

               -  Idarubicin

          -  No prior mitoxantrone

          -  No prior high-dose chemotherapy for bone marrow transplantation

          -  More than 4 weeks since prior chemotherapy (6 weeks for nitrosoureas or mitomycin)

          -  At least 3 weeks since prior radiotherapy

          -  At least 3 weeks since prior surgery

          -  More than 4 weeks since prior investigational drugs

          -  No other concurrent anticancer therapy or agents
Clinical trial NCT00054938 (phase 2, status: completed)
Conditions: systemic lupus erythematosus, lupus
ICD codes: M32.9, M32.0, M32.11, M32.12, M32.13, M32.14, M32.8, D68.62, L93.0, L93.1, L93.2, M32.9, M32.0, M32.11
Drugs: pravastatin, aspirin, ramipril, vitamins: b6, b12, and folate
SMILES: CC(C)C1=C(C(=O)NC2=CC=CC=C2)C(=C(N1CC[C@@H](O)C[C@@H](O)CC(O)=O)C1=CC=C(F)C=C1)C1=CC=CC=C1, CC(=O)OC1=CC=CC=C1C(O)=O, [H][C@@]12CCC[C@]1([H])N([C@@H](C2)C(O)=O)C(=O)[C@H](C)N[C@@H](CCC1=CC=CC=C1)C(=O)OCC, NC1=NC(=O)C2=NC(CNC3=CC=C(C=C3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)=CN=C2N1
Eligibility criteria:

        Inclusion Criteria

          -  SLE as defined by the 1997 American College of Rheumatology criteria

          -  Acceptable methods of contraception

        Exclusion Criteria

          -  Participation in another experimental protocol for ASVD prevention

          -  Heavy alcohol consumption ( >= 3 drinks/day)

          -  Aspirin intolerance

          -  Certain medications, including coumadin, ACE inhibitors, potassium supplements,
             potassium sparing diuretics, cyclosporine, and lithium

          -  Peptic ulcer disease within 6 months prior to study entry

          -  History of an intracranial bleed or brain tumor

          -  Bleeding diathesis

          -  History of allergy or sensitivity to ACE inhibitors

          -  Uncontrolled high blood pressure (180 mm Hg/110 mm Hg)

          -  Creatinine > 2.0 mg/dl

          -  Renal artery stenosis

          -  Pregnant or breastfeeding

          -  Abnormal liver function tests (ALT > 2 X upper limit of normal)

          -  History of a muscle disease, or baseline CPK > 500U/L or 2 X upper limit of normal
Clinical trial NCT00494780 (phase 2, status: completed)
Conditions: lymphoma, follicular
ICD codes: S33.110S, S33.111S, S33.120S, S33.121S, S33.130S, S33.131S, S33.140S
Drugs: ofatumumab, cyclophosphamide, doxorubicin, vincristine, prednisolone, prednisone or equivalent
SMILES: ClCCN(CCCl)P1(=O)NCCCO1, COC1=CC=CC2=C1C(=O)C1=C(O)C3=C(C[C@](O)(C[C@@H]3O[C@H]3C[C@H](N)[C@H](O)[C@H](C)O3)C(=O)CO)C(O)=C1C2=O, CC[C@]1(O)C[C@@H]2CN(C1)CCC1=C(NC3=CC=CC=C13)[C@@](C2)(C(=O)OC)C1=C(OC)C=C2N(C=O)[C@@H]3[C@]4(CCN5CC=C[C@](CC)([C@@H]45)[C@@H](OC(C)=O)[C@]3(O)C(=O)OC)C2=C1, [H][C@@]12CC=C(C3=CC=CN=C3)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC=C2C[C@@H](O)CC[C@]12C
Eligibility criteria:

        Inclusion Criteria:

          -  Patient with Follicular Lymphoma (FL)

          -  Confirmed diagnosis of Follicular lymphoma

          -  18 years or above

          -  Verbal and written information about the study

        Exclusion Criteria:

          -  No previous treatment for Follicular Lymphoma

          -  Clinical suspicion that the Follicular Lymphoma has transformed to aggressive lymphoma

          -  Several diseases such as malignancies etc.

          -  Screening laboratory values

          -  Current participation in any other interventional clinical study

          -  Breast feeding women or pregnant women

          -  Women of childbearing potential not willing to use adequate contraception
Clinical trial NCT00661167 (phase 2, status: completed)
Conditions: gastric cancer
ICD codes: C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, C17.2
Drugs: abi-007
SMILES: [H][C@]12[C@H](OC(=O)C3=CC=CC=C3)[C@]3(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)C4=CC=CC=C4)C4=CC=CC=C4)C(C)=C([C@@H](OC(C)=O)C(=O)[C@]1(C)[C@@H](O)C[C@H]1OC[C@@]21OC(C)=O)C3(C)C
Eligibility criteria:

        Inclusion Criteria:

          -  Histologically or cytologically confirmed gastric adenocarcinoma

          -  Received one prior regimen containing fluoropyrimidine analogs and developed disease
             progression or recurrence

          -  Age: 20 - 74

          -  At least one measurable lesion by RECIST criteria

        Exclusion Criteria:

          -  History of Taxans use

          -  Patients with another active malignancy

          -  Pre-existing peripheral neuropathy of Grade 2, 3, or 4 (per CTCAE)

          -  Chronic treatment with steroids
Clinical trial NCT00648245 (phase 2, status: completed)
Conditions: copd, chronic obstructive pulmonary disease
ICD codes: J44.9, J44.1, J44.0
Drugs: bio-11006 inhalation solution, bio-11006 inhalation solution, bio-11006 inhalation solution, placebo, bio-11006
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Clinically stable male or female outpatients, 45 years of age or older

          -  Active COPD with chronic bronchitis indicated by: (1) FEV1 = 40% to 70%, (2) FEV1/FVC
             ≤70%, (3)Chronic productive cough for 3 months in each of 2 successive years, and (4)
             Sputum (phlegm) production at least several days a week over the past 4 weeks

          -  Current or previous smoker with a 20-pack year history

        Exclusion Criteria:

          -  Treatment with oral prednisone during the 6 weeks before enrollment

          -  Changed inhaled corticosteroid dose or long acting bronchodilator dose during the 6
             weeks before enrollment

          -  Treatment with oxygen (with the exception of night time oxygen) during the 6 weeks
             before enrollment

          -  Current asthma as determined by the investigator

          -  Change in smoking status during the previous 6 months
Clinical trial NCT01128595 (phase 2, status: completed)
Conditions: asthma
ICD codes: J45.998, J82.83, J45.909, J45.991, J45.20, J45.30, J45.40
Drugs: ff/gw642444m, gw642444m, fluticasone furoate, placebo
SMILES: OCC1=C(O)C=CC(=C1)[C@@H](O)CNCCCCCCOCCOCC1=C(Cl)C=CC=C1Cl, OCC1=C(O)C=CC(=C1)[C@@H](O)CNCCCCCCOCCOCC1=C(Cl)C=CC=C1Cl, [H][C@@]12C[C@@H](C)[C@](OC(=O)CC)(C(=O)SCF)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])C[C@H](F)C2=CC(=O)C=C[C@]12C, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

        - Body mass index within the range 18.5-35.0 kilograms/metre2 (kg/m2).

          -  Females of non-child bearing potential.

          -  Documented history of bronchial asthma, first diagnosed at least 6 months prior to the
             screening visit and currently being treated only with intermittent short-acting beta
             -agonist therapy by inhalation

          -  Pre-bronchodilator FEV1 >70% of predicted at screening

          -  Subjects who are current non-smokers

          -  Methacholine challenge PC20 < 8 mg/mL at screening

          -  Screening allergen challenge demonstrates that the subject experiences an early
             asthmatic response

        Exclusion Criteria:

          -  Current or chronic history of liver disease, or known hepatic or biliary abnormalities

               -  Subject is hypertensive at screening

               -  Respiratory tract infection and/or exacerbation of asthma within 4 weeks prior to
                  the first dose of study medication.

               -  History of life-threatening asthma

               -  Symptomatic with hay fever at screening or predicted to have symptomatic hayfever

               -  Unable to abstain from short acting beta agonists

               -  Unable to abstain from antihistamines

               -  Unable to abstain from other medications including non-steroidal
                  anti-inflammatory drugs (NSAIDs), anti-depressant drugs, anti-asthma
                  anti-rhinitis or hay fever medication

               -  The subject has participated in a study with a new molecular entity during the
                  previous 3 months or has participated in 4 or more clinical studies in the
                  previous 12 months

               -  undergoing allergen desensitisation therapy